YCBD:NYE-cbdMD Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.377

Change

+0.02 (+4.43)%

Market Cap

USD 1.96M

Volume

0.52M

Analyst Target

USD 5.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-27 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 74.37B
HLN Haleon plc

N/A

USD 44.13B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 42.24B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 13.11B
CTLT Catalent Inc

N/A

USD 11.52B
ELAN Elanco Animal Health

N/A

USD 5.75B
AMRX Amneal Pharmaceuticals, Inc. C..

N/A

USD 3.59B
BHC Bausch Health Companies Inc

N/A

USD 2.75B
CPHI China Pharma Holdings Inc

N/A

USD 3.69M
PBH Prestige Brand Holdings Inc

N/A

N/A

ETFs Containing YCBD

PSY 0.00 % 0.76 %

N/A

N/A
MJUS Amplify ETF Trust 0.00 % 0.00 %

N/A

USD 0.15B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -63.75% 13% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -63.75% 13% F 2% F
Trailing 12 Months  
Capital Gain -63.75% 13% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -63.75% 13% F 2% F
Trailing 5 Years  
Capital Gain -99.68% 7% C- N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.68% 7% C- N/A F
Average Annual (5 Year Horizon)  
Capital Gain 70.26% 100% F 95% A
Dividend Return 70.26% 100% F 95% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 514.74% 7% C- 3% F
Risk Adjusted Return 13.65% 53% F 29% F
Market Capitalization 1.96M 10% F 1% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector